FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours

摘要: Gastrointestinal stromal tumours (GISTs) are fairly rare neoplasms, constituting less than 3 % of all gastrointestinal malignancies. The integration molecularly targeted treatment regimes (i.e., tyrosine kinase inhibitors) in clinical oncology has revolutionized the management patients with irresectable GISTs or metastatic disease. Malignant usually display increased glucose metabolism and therefore 18F-fluorodeoxyglucose (FDG) uptake within scope positron emission tomography (PET) scans. Nowadays, dual-modality FDG PET/CT (computed tomography) imaging is considerable value diagnostic work-up acquiring functional anatomic information simultaneously. following article sheds light on impact PET combined initial disease evaluation, detection tumour recurrence early assessment response to agents such as imatinib mesylate sunitinib maleate.